Risperidone

Earn CME/CE in your profession:

Free Review Questions

Continuing Education Activity

Risperidone is an antipsychotic medication approved for the treatment of various conditions, including schizophrenia, bipolar I disorder with acute manic or mixed episodes, and autism-associated irritability. The long-acting injectable form of risperidone is approved for the treatment and maintenance of schizophrenia and as monotherapy or adjunctive therapy with valproate or lithium for the maintenance of bipolar disorder in adults.

This educational activity covers FDA-approved indications, mechanisms of action, administration methods, adverse events, contraindications, and monitoring requirements of risperidone. The discussion focuses on evidence-based strategies to optimize the effectiveness of risperidone while reducing potential adverse effects. This program underscores the critical role of the interprofessional healthcare team in managing risperidone therapy and supporting safe and individualized treatment.

Objectives:

  • Identify risperidone's mechanism of action.

  • Assess the indications for risperidone therapy.

  • Evaluate the adverse event profile for risperidone.

  • Implement effective collaboration and communication among interprofessional team members to improve treatment efficacy for patients who might benefit from risperidone therapy.

Indications

Risperidone is an atypical antipsychotic medication that was first approved by the United States Food and Drug Administration (FDA) in 1993. The American Psychiatric Association (APA) advises that patients with schizophrenia should receive treatment with an antipsychotic medication, along with careful monitoring for effectiveness and potential adverse effects. Furthermore, the APA emphasizes that those who experience improvement of symptoms during antipsychotic therapy should maintain their treatment regimen.[1]

FDA-Approved Indications

The FDA-approved indications for oral risperidone (tablets, oral solution, and meltable tablets) include:

  • Schizophrenia (adults and children 13 and older)
  • Bipolar I acute manic or mixed episodes as monotherapy (adults and children 10 and older)
  • Bipolar I acute manic or mixed episodes adjunctive with lithium or valproate (adults) [2]
  • Autism-associated irritability (children aged 5 and older) [3]

The long-acting risperidone injection has received FDA approval as a treatment for schizophrenia and maintenance of bipolar disorder (as monotherapy or adjunctive to valproate or lithium) in adults.

Off-Label Uses

Risperidone has been used to treat various psychotic symptoms when they are present. This medication has also been used to treat borderline personality disorder, delusional disorder, delirium, depression, various brain injuries, pedophilia, posttraumatic stress injury, bipolar disorder, conduct disorder, Lesch-Nyhan syndrome, Tourette syndrome, trichotillomania, speech disorders (eg, stuttering), movement disorders, and developmental disorders.[4][5][6][7][8] In addition to psychotic symptoms, risperidone is also prescribed to treat aggression and agitation in patients with dementia, to augment antidepressant therapy for patients with non-psychotic unipolar depression, and for social impairment, stereotypical behaviors, cognitive problems, and hyperactivity in patients with autism.[9][10][11]

Mechanism of Action

All antipsychotics exhibit some degree of antagonism at dopamine D2 receptors. First-generation antipsychotics (FGAs) produce observable antipsychotic effects at 60% to 80% D2 occupancy. Second-generation antipsychotics (SGAs) like risperidone exhibit some D2 blockade, but their effects are more the result of blocking serotonin receptors like 5HT2A. SGAs bind loosely to D2 receptors and can quickly dissociate from them, possibly explaining their lower likelihood of causing extrapyramidal symptoms.[12]

Moreover, SGAs exhibit agonist activity at the 5HT1A receptor. Risperidone's antidepressant effects are thought to involve serotonin and norepinephrine reuptake inhibition. Positive symptoms are thought to result from the blockade of D2 receptors in the mesolimbic pathway. The ability of antipsychotics to block D2 receptors in the prefrontal cortex and nucleus accumbens is essential in improving various psychiatric symptoms. Risperidone does not cause anticholinergic effects, which may benefit patients in specific populations, including older patients with dementia. Despite these advantages, risperidone must be prescribed cautiously (see the Contraindications section).

Pharmacokinetics

Absorption: After a single intramuscular injection of risperidone (extended-release injectable suspension), there is a minor initial release of the drug (<1% of the dose), followed by a lag time of about 3 weeks. The major release begins at 3 weeks, is maintained from the fourth to the sixth week, and subsides by 7 weeks post-injection. Therefore, it is essential to provide oral antipsychotic supplementation during the first 3 weeks to maintain therapeutic levels until the primary release of risperidone occurs.

Distribution: Risperidone is rapidly distributed throughout the body, with a volume of distribution ranging from 1 to 2 L/kg. The drug is approximately 90% bound to plasma proteins (ie, albumin and α-acid glycoprotein), while its major metabolite, 9-hydroxy-risperidone, has a plasma protein binding of around 77%. Both deltoid and gluteal intramuscular injections are bioequivalent, making them interchangeable.

Metabolism: Risperidone undergoes extensive hepatic metabolism, primarily through hydroxylation to 9-hydroxy-risperidone via the CYP2D6 enzyme. This metabolite possesses pharmacological activity similar to risperidone, so the clinical effect results from the combined concentrations of both compounds. Genetic polymorphisms affecting CYP2D6 can influence metabolism, leading to some individuals being classified as "extensive" or "poor" metabolizers.[13] Medications that inhibit CYP2D6 (eg, quinidine) can impede this conversion, leading to a pharmacokinetic profile similar to that of poor metabolizers. Conversely, enzyme inducers (eg, carbamazepine) can reduce the plasma concentrations of risperidone and 9-hydroxy-risperidone. The apparent half-life of risperidone and 9-hydroxy-risperidone following administration of the extended-release injectable suspension is 3 to 6 days, correlating with the degradation of the microspheres and subsequent absorption. In contrast, the oral formulation has a mean half-life of approximately 20 hours.

Elimination: Risperidone and its metabolites are primarily eliminated through urine, with some excretion via feces. Long-term (up to 12 months) administration of the injectable form at doses of 25 mg or 50 mg every 2 weeks does not result in any significant accumulation of risperidone. Complete elimination following this regimen occurs 7 to 8 weeks after the last injection.

Administration

Available Dosage Forms and Strengths

Risperidone may be administered orally (tablets, solution, or dissolvable) or as a long-acting injection. The oral forms are available in strengths of 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. The oral solution is available at a concentration of 1 mg/mL. Risperidone is also available as orally disintegrating tablets in the following strengths: 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg. Patients should not cut or chew the orally disintegrating tablet formulation.

Risperidone is also available in injectable form. The extended-release intramuscular formulation is available in 12.5 mg, 25 mg, 37.5 mg, and 50 mg doses. A prefilled syringe for subcutaneous administration is available in 90 mg and 120 mg solutions. Subcutaneous syringes containing 50 mg, 75 mg, 100mg, 125 mg, 150 mg, 175 mg, 200 mg, and 250 mg doses are also available.

Adult Dosage

Schizophrenia

Oral 

Initiation: For the first episode, take 1 to 3 mg orally once daily or divided into 2 doses. Clinicians should prescribe 1 mg daily and increase the dose by 0.5 mg every 6 to 7 days to target 2 mg daily. The maximum daily dose is 16 mg, but daily doses exceeding 4 mg are rarely more effective.

Maintenance: 1 to 4 mg orally once daily or divided into 2 doses. Start at 1 to 2 mg daily, then increase the dose by 0.5 mg daily every 3 to 7 days to a target daily dose of 4 mg. The maximum daily dose is 16 mg, but daily doses exceeding 4 mg are rarely more effective and are associated with higher rates of adverse drug reactions.

Patients 65 and older: 1 to 4 mg orally once daily or divided into 2 doses. Start at 0.25 to 0.5 mg daily, then increase the dose by 0.5 mg daily every 6 to 7 days to a target daily dose of 2 mg.

Subcutaneous

Test tolerability with a trial of oral risperidone before initiating injection therapy. Loading doses or overlaps with oral risperidone are not required. Begin administering subcutaneous extended-release (SubQ ER) the day after the last oral dose.

Perseris: 90 or 120 mg once monthly

  • Oral 3 mg daily = SubQ ER 90 mg once monthly
  • Oral 4 mg daily = SubQ ER 120 mg once monthly

Uzedy: 50 to 125 mg once monthly or 100 to 250 mg every 2 months

  • Oral 2 mg daily = SubQ 50 mg once monthly or 100 mg every 2 months
  • Oral 3 mg daily = SubQ 75 mg once monthly or 150 mg every 2 months
  • Oral 4 mg daily = SubQ 100 mg once monthly or 200 mg every 2 months
  • Oral 5 mg daily = SubQ 125 mg once monthly or 250 mg every 2 months

Intramuscular

Test risperidone tolerability by trial with oral risperidone before initiating injection therapy. Due to the delayed onset of action, the first injection should be overlapped with an oral antipsychotic drug at an effective dose for the first week (Rykindo) or the first 3 weeks (Risperdal Consta).

Initiation: Administer 25 mg every 2 weeks. Based on tolerability and response, increase the dosage (12.5 to 25 mg) every 4 weeks. The maximum recommended dosage is 50 mg every 2 weeks.

The American Psychiatric Association guidelines for the treatment of patients with schizophrenia recommend the following conversions from oral to intramuscular extended-release (IM ER) dosages when needed.[1]

  • LT 3 mg orally daily = 25 mg IM
  • 3 to 5 mg orally daily = 37.5 mg IM
  • MT 5 mg orally daily = 50 mg IM

When switching from Risperdal Consta IM ER to Rykindo IM ER, administer the exact dosage. The first dose of Rykindo should be administered 4 to 5 weeks after the last dose of Risperdal Consta.

Bipolar I with acute manic or mixed episodes

  • The typical dose is 1 to 6 mg orally once daily or divided into 2 doses. Start at 2 to 3 mg daily, then increase the dose by 1 mg daily no more frequently than every 24 hours to target 2 mg daily. The maximum dose is 6 mg daily.

Tourette syndrome

  • The typical dose is 0.2 to 3 mg orally once daily or divided into 2 doses. The maximum dose is 6 mg daily.

Specific Patient Populations

Hepatic impairment: For Child-Pugh Class C, start at 0.5 mg orally twice daily. This may be increased by 0.5 mg up to 1.5 mg twice daily, after which dosing should not increase more frequently than once a week.

Renal impairment: For CrCl <30 mL/min/1.73m2, start at 0.5 mg orally twice daily. This may be increased by 0.5 mg up to 1.5 mg twice daily, after which dosing should not increase more frequently than once a week.

Pregnancy considerations: Risperidone can cross the placenta and potentially cause extrapyramidal or withdrawal symptoms in neonates exposed during the third trimester. Recent studies have not established a definitive link between risperidone and significant birth defects, miscarriage, or adverse maternal or fetal outcomes. Untreated schizophrenia or bipolar I disorder poses risks, including relapse, hospitalization, increased suicide risk, and adverse perinatal outcomes.[14][15] Neonates exposed to risperidone in utero may experience agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, and feeding disorders. These symptoms vary in severity; some recover quickly, while others may require extended hospitalization. While studies show no clear association between atypical antipsychotic use and significant birth defects, a mild increase in the risk of major birth defects and cardiac malformations with risperidone exposure during the first trimester has been observed. Providers are encouraged to register patients receiving atypical antipsychotics in the National Pregnancy Registry (phone: 1-866-961-2388), which monitors outcomes nationwide.

Breastfeeding considerations: Low levels of risperidone have been detected in the breast milk of mothers receiving daily doses of up to 6 mg. Infants exposed to risperidone may experience sedation, failure to thrive, jitteriness, tremors, abnormal muscle movements, and respiratory depression. Due to limited data, other medications may be preferred, especially for nursing newborns or preterm infants. Risperidone is generally considered a second-line antipsychotic during breastfeeding due to its relatively high excretion into milk. Caution is advised, and infants should be monitored for drowsiness, weight gain, tremors, respiratory rate, abnormal movements, and developmental milestones, especially if the patient is receiving or has previously received other antipsychotics.[16]

Pediatric patients: Risperidone is FDA-approved for managing irritability associated with autism. Risperidone dosage should be individualized based on patient response and tolerability. The total daily dose can be administered all at once or split into 2 doses. For patients weighing less than 20 kg, initiate at 0.25 mg daily; for patients weighing 20 kg or more, start at 0.5 mg daily. After 4 days, increase to 0.5 mg for those under 20 kg and 1.0 mg for those 20 kg or more, maintaining for 14 days. Further increases can occur every 2 weeks in 0.25 or 0.5 mg increments. The effective dose range is 0.5 mg to 3 mg per day. No data for children weighing less than 15 kg is available. Once a sufficient response is achieved, gradual dose reduction should be considered. Regularly reassess the long-term risks and benefits. A bedtime dose or adjustment may be beneficial for patients with persistent somnolence.

Older patients: In older patients, a lower starting dose of risperidone is recommended due to decreased clearance and a higher likelihood of hepatic, renal, or cardiac impairment. To minimize the risk of orthostatic hypotension, initiate with 0.5 mg twice daily and titrate carefully. Monitoring of orthostatic vital signs may be necessary. Risperidone is primarily excreted by the kidneys, which increases the risk of toxicity in those with renal impairment. Since older patients often have reduced renal function, careful dose selection and renal function monitoring are advised. Please refer to the Contraindications section of this article regarding the risk of mortality for patients with dementia.

Adverse Effects

Patients receiving risperidone may experience significant weight changes, metabolic changes, and sedation. Risperidone may produce extrapyramidal symptoms (EPS), including acute dystonia, akathisia, tardive dyskinesia (TD), and parkinsonism. Acute/early EPS can occur at the beginning of treatment or when the dose is adjusted. Late-onset EPS (tardive dyskinesia) typically results from chronic treatment. Akathisia is a feeling of restlessness and may manifest as the patient pacing. Acute dystonia includes muscle spasms that result in abnormal postures and typically affect the head and neck. Parkinsonian features include skeletal muscle rigidity (often described as "cogwheel rigidity"), tremor, shuffling gait, and bradykinesia. Movements of the limbs, torso, neck, and head (commonly involving the tongue and lips) characterize tardive dyskinesia. This may also appear as facial grimacing or oculogyric crisis. EPS is thought to be caused by D2 blockade in the nigrostriatal pathway. Since acute EPS symptoms often improve after discontinuing the medication, these adverse effects are a significant cause of noncompliance with treatment.

Although these adverse effects are thought to be reversible, the duration of Parkinsonian features after discontinuation of the medication can vary. Tardive dyskinesia, however, will likely persist after the medication is discontinued and may be permanent. In addition to discontinuation of the antipsychotic, pharmacologic treatments are available that may help with certain extrapyramidal symptoms.[17][18] One potential adverse effect of risperidone is orthostatic hypotension. 

The antagonism of D2 receptors in the tuberoinfundibular pathway is associated with a rise in prolactin levels. The resulting hyperprolactinemia can precipitate sexual dysfunction, which occurs in 45% to 80% of males and 30% to 80% of females taking this medication. Elevated prolactin can contribute to decreased libido, impaired arousal, and difficulty attaining orgasm. Sexual adverse effects may also be precipitated by risperidone's action at adrenergic (α1, α2) and histamine (H2) receptors. Gynecomastia, galactorrhea, and priapism have been reported in men, while galactorrhea and amenorrhea have been reported in women. Children may be more susceptible to specific adverse effects and require careful monitoring.[19]

Severe adverse drug reactions of antipsychotic medications (like risperidone) can include neuroleptic malignant syndrome (NMS). Although the pathogenesis of NMS is not clear, it is a life-threatening condition that can manifest with altered mental status, fever, "lead pipe" rigidity, and autonomic instability, including hypertension, tachypnea, and tachycardia. The use of risperidone has also been linked to a higher probability of cerebrovascular events in older patients with dementia, leading to an FDA warning about using this medication in the context of dementia-related psychosis. Studies have also shown an increase in all-cause mortality among older patients with dementia who receive this medication.[20] Various case reports have identified patients on long-term risperidone treatment who exhibited typical features of intraoperative floppy iris syndrome during cataract surgery.[21][22]

Drug-Drug Interactions

  • Fluoxetine: Fluoxetine increases risperidone levels due to CYP2D6 inhibition; the dose should be lowered to prevent toxicity.

  • Paroxetine: Similar to fluoxetine, paroxetine raises risperidone levels, which may require dose adjustments.

  • Carbamazepine: Carbamazepine induces CYP3A, potentially lowering risperidone levels; titrate upwards but do not exceed twice the usual dose.

  • Alcohol: Caution is recommended when combining risperidone with other CNS depressants and alcohol due to potential additive effects.

  • Levodopa and dopamine agonists: Risperidone may antagonize the effects of dopamine agonists and levodopa, potentially reducing their efficacy.

  • Methylphenidate: Co-administration with methylphenidate may increase the risk of extrapyramidal symptoms, necessitating monitoring for these symptoms.

  • Clozapine: Chronic use of clozapine may reduce the clearance of risperidone, which could require dose adjustments.

Contraindications

Risperidone should not be given to a patient with a known allergy or hypersensitivity to risperidone or paliperidone (a risperidone metabolite).

Box Warnings

The use of risperidone has also been linked to a higher probability of cerebrovascular events in older patients with dementia, leading to an FDA warning about using this medication in the context of dementia-related psychosis. Studies have even shown an increase in all-cause mortality among older patients with dementia who are on this medication.[20]

Warnings and Precautions

Hallucinogen-persistent perception disorder (HPPD): HPDD may be a relative contraindication for risperidone because some patients treated with risperidone for their HPPD reported that panic and visual symptoms intensified.[23]

Seizures: Seizures have been reported in risperidone-treated patients, with some cases linked to hyponatremia. Caution is advised when prescribing risperidone to patients with a history of seizures.[24]

Phenylketonuria: Clinicians should inform patients that risperidone orally disintegrating tablets contain phenylalanine, a component of aspartame.

Monitoring

Although there are no mandatory requirements for therapeutic drug monitoring with risperidone, monitoring plasma concentrations for this medication is strongly recommended by European guidelines because of data showing interdependent variability. Therapeutic monitoring can benefit from assessing compliance and identifying low drug concentrations that may be low, resulting in therapeutic failure. Also, monitoring the drug level can aid in evaluating potential drug interactions and adverse effects.

Specific parameters should be monitored while the patient is on antipsychotics, especially in children who are more sensitive to adverse effects. When using risperidone, the clinician may derive patient benefit by monitoring serum prolactin, hepatic functioning, metabolic functioning, thyroid functioning, weight or body mass index, height, waist circumference, blood pressure, fasting plasma glucose, insulin, fasting lipid profile, and QTc interval.[25][26] Clinicians can also use the Abnormal Involuntary Movement Scale (AIMS) as a monitoring tool.[27]

Toxicity

Signs and Symptoms of Overdose

Overdoses of risperidone typically do not result in fatalities, instead manifesting as symptoms that include drowsiness, sedation, tachycardia, hypotension, and extrapyramidal effects, reflecting an extension of its pharmacological action. Hyponatremia, prolonged QT interval, and seizures have been documented. Postmarketing reports include similar symptoms with additional occurrences of protracted QT and convulsions. Torsade de pointes has been observed in instances of concurrent overdose with risperidone and paroxetine.[28]

Management of Overdose

Consult a poison control center (phone: 1-800-222-1222) or a medical toxicologist for management. Provide supportive care, monitor vital signs, and ensure airway safety. There is no specific antidote for risperidone.

Enhancing Healthcare Team Outcomes

An interprofessional healthcare team consisting of physicians and advanced practice providers who prescribe risperidone must monitor the patient closely. Nurses and pharmacists are also crucial in patient monitoring and directing drug administration. The drug has many adverse effects, of which the most significant are weight gain, metabolic changes, and sedation. Unlike the older antipsychotics, tardive dyskinesia is less frequently observed with the newer atypical antipsychotics like risperidone.[29][30] Nevertheless, the healthcare team is responsible for detecting and managing any movement disorder. Countless litigations have occurred chiefly due to the lack of proper management of the adverse effects of risperidone. Interprofessional communication and collaboration are essential to achieving the best therapeutic goal.[31]

Severe adverse effects of antipsychotic medications (like risperidone) can include NMS. Although the pathogenesis of NMS is not clear, it is a life-threatening condition that can manifest with altered mental status, fever, "lead pipe" rigidity, and autonomic instability, which may manifest as hypertension, tachypnea, and tachycardia. The use of risperidone has also been linked to a higher probability of cerebrovascular events in older patients with dementia, leading to an FDA warning about the use of this medication in the context of dementia-related psychosis. Studies have also shown an increase in all-cause mortality among older patients with dementia who are on this medication.[32][29] In overdose, emergency medicine physicians should rapidly stabilize the patient. Psychiatry consultation is required if the overdose is intentional. An interprofessional team approach and communication among clinicians, pharmacists, and nurses are crucial to decreasing potential adverse effects and improving disease course and patient outcomes related to risperidone.

Details

Author

Shawn E. McNeil

Author

Jonathan R. Gibbons

Editor:

Mark Cogburn

Updated:

11/10/2024 12:00:05 AM

Feedback:

Send Us Your Comments

References

[1]

Keepers GA, Fochtmann LJ, Anzia JM, Benjamin S, Lyness JM, Mojtabai R, Servis M, Walaszek A, Buckley P, Lenzenweger MF, Young AS, Degenhardt A, Hong SH, (Systematic Review). The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. The American journal of psychiatry. 2020 Sep 1:177(9):868-872. doi: 10.1176/appi.ajp.2020.177901. Epub     [PubMed PMID: 32867516]

Level 1 (high-level) evidence

[2]

Nestsiarovich A, Gaudiot CES, Baldessarini RJ, Vieta E, Zhu Y, Tohen M. Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2022 Jan:54():75-89. doi: 10.1016/j.euroneuro.2021.08.264. Epub 2021 Sep 3     [PubMed PMID: 34489127]

Level 1 (high-level) evidence

[3]

Siafis S, Çıray O, Wu H, Schneider-Thoma J, Bighelli I, Krause M, Rodolico A, Ceraso A, Deste G, Huhn M, Fraguas D, San José Cáceres A, Mavridis D, Charman T, Murphy DG, Parellada M, Arango C, Leucht S. Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis. Molecular autism. 2022 Mar 4:13(1):10. doi: 10.1186/s13229-022-00488-4. Epub 2022 Mar 4     [PubMed PMID: 35246237]

Level 1 (high-level) evidence

[4]

Boman L, De Butte M. Neurobehavioral effects of chronic low-dose risperidone administration in juvenile male rats. Behavioural brain research. 2019 May 2:363():155-160. doi: 10.1016/j.bbr.2019.02.009. Epub 2019 Feb 5     [PubMed PMID: 30735760]

[5]

Putignano D, Clavenna A, Reale L, Bonati M. The evidence-based choice for antipsychotics in children and adolescents should be guaranteed. European journal of clinical pharmacology. 2019 Jun:75(6):769-776. doi: 10.1007/s00228-019-02641-0. Epub 2019 Feb 7     [PubMed PMID: 30729258]

[6]

Farhat LC, Behling E, Landeros-Weisenberger A, Levine JLS, Macul Ferreira de Barros P, Wang Z, Bloch MH. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet. Child & adolescent health. 2023 Feb:7(2):112-126. doi: 10.1016/S2352-4642(22)00316-9. Epub 2022 Dec 14     [PubMed PMID: 36528030]

Level 1 (high-level) evidence

[7]

Momosaki K, Kido J, Matsumoto S, Taniguchi A, Akiyama T, Sawada T, Ozasa S, Nakamura K. The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease: A Case Report. Case reports in neurology. 2019 Sep-Dec:11(3):256-264. doi: 10.1159/000502568. Epub 2019 Sep 19     [PubMed PMID: 31607891]

Level 3 (low-level) evidence

[8]

Krajewski PK, Zirpel H, Saceda-Corralo D, Thaçi D, Szepietowski JC. Exploring pharmacological treatment for trichotillomania: do we need better education? International journal of dermatology. 2024 May 26:():. doi: 10.1111/ijd.17269. Epub 2024 May 26     [PubMed PMID: 38797877]

[9]

Feiner B, Chase KA, Melbourne JK, Rosen C, Sharma RP. Risperidone effects on heterochromatin: the role of kinase signaling. Clinical and experimental immunology. 2019 Apr:196(1):67-75. doi: 10.1111/cei.13250. Epub 2019 Feb 3     [PubMed PMID: 30714144]

[10]

Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis. Journal of child and adolescent psychopharmacology. 2019 Apr:29(3):168-180. doi: 10.1089/cap.2018.0115. Epub 2019 Feb 1     [PubMed PMID: 30707602]

Level 1 (high-level) evidence

[11]

Feng XZ, Li Z, Li ZY, Wang K, Tan X, Zhao YY, Mi WF, Zhu WL, Bao YP, Lu L, Li SX. Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis. Psychiatry research. 2024 Feb:332():115637. doi: 10.1016/j.psychres.2023.115637. Epub 2023 Dec 2     [PubMed PMID: 38150810]

Level 1 (high-level) evidence

[12]

Meltzer HY, Gadaleta E. Contrasting Typical and Atypical Antipsychotic Drugs. Focus (American Psychiatric Publishing). 2021 Jan:19(1):3-13. doi: 10.1176/appi.focus.20200051. Epub 2021 Jan 25     [PubMed PMID: 34483761]

[13]

. Risperidone. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:():     [PubMed PMID: 31644213]

[14]

Larsen ER, Damkier P, Pedersen LH, Fenger-Gron J, Mikkelsen RL, Nielsen RE, Linde VJ, Knudsen HE, Skaarup L, Videbech P, Danish Psychiatric Society, Danish Society of Obstetrics and Gynecology, Danish Paediatric Society, Danish Society of Clinical Pharmacology. Use of psychotropic drugs during pregnancy and breast-feeding. Acta psychiatrica Scandinavica. Supplementum. 2015:(445):1-28. doi: 10.1111/acps.12479. Epub     [PubMed PMID: 26344706]

[15]

ACOG Committee on Practice Bulletins--Obstetrics. ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation. Obstetrics and gynecology. 2008 Apr:111(4):1001-20. doi: 10.1097/AOG.0b013e31816fd910. Epub     [PubMed PMID: 18378767]

[16]

. Risperidone. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 30000154]

[17]

Stogios N, Smith E, Bowden S, Tran V, Asgariroozbehani R, McIntyre WB, Remington G, Siskind D, Agarwal SM, Hahn MK. Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2022 Feb:47(3):664-672. doi: 10.1038/s41386-021-01163-7. Epub 2021 Aug 26     [PubMed PMID: 34446830]

Level 1 (high-level) evidence

[18]

Jiwanmall SA, Gopalakrishnan R, Kuruvilla A. Tardive laryngeal dystonia with risperidone - A case report. Indian journal of psychiatry. 2021 May-Jun:63(3):306-307. doi: 10.4103/psychiatry.IndianJPsychiatry_340_20. Epub 2021 Jun 17     [PubMed PMID: 34211231]

Level 3 (low-level) evidence

[19]

Trinchieri M, Trinchieri M, Perletti G, Magri V, Stamatiou K, Cai T, Montanari E, Trinchieri A. Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review. The journal of sexual medicine. 2021 Aug:18(8):1354-1363. doi: 10.1016/j.jsxm.2021.05.016. Epub 2021 Jul 8     [PubMed PMID: 34247952]

Level 1 (high-level) evidence

[20]

Misawa F, Okumura Y, Takeuchi Y, Fujii Y, Takeuchi H. Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan. Schizophrenia research. 2021 May:231():42-46. doi: 10.1016/j.schres.2021.02.016. Epub 2021 Mar 19     [PubMed PMID: 33752105]

[21]

Ford RL, Sallam A, Towler HM. Intraoperative floppy iris syndrome associated with risperidone intake. European journal of ophthalmology. 2011 Mar-Apr:21(2):210-1     [PubMed PMID: 20853271]

[22]

Matsuo M, Sano I, Ikeda Y, Fujihara E, Tanito M. Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2016 Aug:51(4):294-296. doi: 10.1016/j.jcjo.2016.02.008. Epub 2016 Jun 30     [PubMed PMID: 27521670]

[23]

Lauterbach EC, Abdelhamid A, Annandale JB. Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade. Pharmacopsychiatry. 2000 Jan:33(1):38-41     [PubMed PMID: 10721882]

[24]

Lee YF, Tsai CK, Liang CS. High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion With Seizure Presentation. Clinical neuropharmacology. 2015 Jul-Aug:38(4):154-5. doi: 10.1097/WNF.0000000000000095. Epub     [PubMed PMID: 26166241]

[25]

Panizzutti B, Bortolasci CC, Spolding B, Kidnapillai S, Connor T, Richardson MF, Truong TTT, Liu ZSJ, Gray L, Kim JH, Dean OM, Berk M, Walder K. Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain. Journal of clinical medicine. 2021 Sep 10:10(18):. doi: 10.3390/jcm10184095. Epub 2021 Sep 10     [PubMed PMID: 34575210]

[26]

Guber KM, Cortes ND, Duan L. Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More. Journal of child and adolescent psychopharmacology. 2022 Feb:32(1):52-60. doi: 10.1089/cap.2021.0021. Epub 2021 Jul 20     [PubMed PMID: 34283934]

[27]

Chakrabarty AC, Bennett JI, Baloch TJ, Shah RP, Hawk C, Natof T. Increasing Abnormal Involuntary Movement Scale (AIMS) Screening for Tardive Dyskinesia in an Outpatient Psychiatry Clinic: A Resident-Led Outpatient Lean Six Sigma Initiative. Cureus. 2023 May:15(5):e39486. doi: 10.7759/cureus.39486. Epub 2023 May 25     [PubMed PMID: 37378259]

[28]

Goto A, Kambayashi R, Izumi-Nakaseko H, Takei Y, Sugiyama A. β-Adrenoceptor blockade can augment the torsadogenic action of risperidone. Journal of pharmacological sciences. 2024 Oct:156(2):134-141. doi: 10.1016/j.jphs.2024.07.011. Epub 2024 Jul 31     [PubMed PMID: 39179332]

[29]

Buhagiar K, Jabbar F. Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis. Clinical drug investigation. 2019 Mar:39(3):253-273. doi: 10.1007/s40261-019-00751-2. Epub     [PubMed PMID: 30675684]

Level 1 (high-level) evidence

[30]

Chen TR, Chen YC. Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up. Frontiers in psychiatry. 2018:9():718. doi: 10.3389/fpsyt.2018.00718. Epub 2018 Dec 18     [PubMed PMID: 30618887]

[31]

Jin B, Liu H. Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis. Journal of neurology. 2019 Oct:266(10):2363-2375. doi: 10.1007/s00415-019-09200-8. Epub 2019 Jan 21     [PubMed PMID: 30666436]

Level 2 (mid-level) evidence

[32]

Pozzi M, Pisano S, Marano G, Carnovale C, Bravaccio C, Rafaniello C, Capuano A, Rossi F, Rizzo R, Bernardini R, Nobile M, Molteni M, Clementi E, Biganzoli E, Radice S. Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. Journal of child and adolescent psychopharmacology. 2019 Mar:29(2):133-140. doi: 10.1089/cap.2018.0092. Epub 2018 Nov 16     [PubMed PMID: 30452281]